ArticleHealth science reports2026
Safety and Efficacy of Remimazolam for General Anesthesia in Elderly Patients Undergoing Transurethral Surgery.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety and Efficacy of Remimazolam for General Anesthesia in Elderly Patients Undergoing Transurethral Surgery.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Remimazolam, a novel benzodiazepine, acts on the GABA receptor and is widely used for procedural sedation. To date, there are relatively few articles comparing remimazolam to propofol for general anesthesia in elderly urology patients. We compared the effectiveness and safety of remimazolam with flumazenil compared to propofol for general anesthesia in patients undergoing geriatric transurethral surgery. Methods: Ninety-six patients were randomly assigned to the propofol group (Group P) and the remimazolam group (Group R) from November 2021 to May 2022. The primary endpoints were the occurrence of hypotension during general anesthesia. The secondary outcomes included the success rate of sedation, intraoperative haemodynamic indices, perioperative inflammatory factor levels, quality of postoperative recovery, duration of extubation and PACU stay, and the incidence of adverse reactions in both groups. Results: Occurrence rate and duration of hypotension were lower in the remimazolam group (50% vs. 69.2%, Conclusion: Remimazolam is both safe and effective for transurethral surgery in elderly patients. However, we need to be mindful of the need for monitoring after extubation and the possibility of a temporary reduction in the quality of recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.